Administration of angiogenesis inhibitors may be more effective if given earlier in the course of prostate cancer progression, prior to a rise in VEGF levels, or in conjunction with other therapeutic interventions such as androgen ablation. This evidence concerns the gene VEGFA and prostate cancer.